Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1139 in healthy volunteers and moderate-to-severe plaque psoriasis
NCT07051538Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2024
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing SHR-1139 Injections Group with Placebo Group (2 arms). Primary endpoints: Adverse Events at 365 days and Serious Adverse Events at 365 days. Started Jun 2024; status: completed.
02
Drugs
SHR-1139
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07051538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07051538.